Difficult toTreat PsA: Mainly Difficult to Define! Dr. Aurelie Najm reports on abstract 0777 from the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/mqjhkfJ39B https://t.co/mdE8IrG27T

• Difficult toTreat PsA: Mainly Difficult to Define! | RheumNow

Reduction of AxSpa-Associated Acute Anterior Uveitis with Certolizumab Acute anterior uveitis (AAU) is the most common extra-musculoskeletal manifestation in axial spondyloarthritis (axSpA), affecting up to 50% of patients in some age groups. https://t.co/HpKk0kUWrb https://t.co/mdaRpVeYI2

• Reduction of AxSpa-Associated Acute Anterior Uveitis with Certolizumab | RheumN…

Effective Treatments for Rheumatoid Arthritis ILD The ACR guidelines for the diagnosis and management of interstitial lung disease, which includes RA-ILD, has been one of the most controversial topics in the runup to ACR Convergence. https://t.co/OWf6Ip2gEw https://t.co/B6zGtNti3t

• Effective Treatments for Rheumatoid Arthritis ILD | RheumNow

Day 2 Report - ACR Plenaries: Changing the Practice of Rheumatology https://t.co/SBFbA40cWu https://t.co/cvbtr2EcJD

• Day 2 Report - ACR Plenaries: Changing the Practice of Rheumatology | RheumNow

Watch: Lupus Nephritis Therapy Paradigm Shift Dr. Yuz Yusof reporting on abstract 0782 at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/m8SgtnVd95 https://t.co/cSexK2PCb5

• Lupus Nephritis Therapy Paradigm Shift | RheumNow

IV Secukinumab for AxSpa The FDA recently announced approval for intravenous secukinumab (Cosentyx) for adults with psoriatic arthritis, ankylosing spondylitis, and non-radiographic spondylitis. https://t.co/JhOvPIXOMN https://t.co/GoV62NjSmf

• IV Secukinumab for AxSpa | RheumNow

How early is early in psoriatic arthritis? Is there a window of opportunity for treatment in PsA to ensure optimal outcomes? https://t.co/VkfQZpbtKA https://t.co/o2Vf9vRo9s

• How early is early in psoriatic arthritis? | RheumNow

Cancer and TNF inhibitors Cancer risk minimisation is a high priority for people with rheumatic diseases, as it is for the general population. Tumor necrosis factor inhibitors (TNFi) have a long history of association with cancer risk discussions https://t.co/fRAkAQ3tw8 https://t.co/Rs8ODYns2t

• Cancer and TNF inhibitors | RheumNow

Watch: SpA Insights: New Therapies https://t.co/fkFYpEnDoX https://t.co/bcVJfl2un2

• SpA Insights: New Therapies | RheumNow

#ACRbest Abstracts – Day 2 Our reporters have been prolific in finding the hot abstracts, those that were most attended or those that are getting the most buzz on social media. Here are RheumNows #ACRbest abstract reports from Monday, 11/13 at #ACR23. https://t.co/qc1PxBKmow https://t.co/leaXyuS2UF

• #ACRbest Abstracts – Day 2 | RheumNow

Lupus Topic Panel Featuring panelists Dr. Kathryn Dao, Eric Dein and Sheila Reyes, discussing the best and most interesting lupus studies presented at #ACR23. https://t.co/4lZmEBH8or https://t.co/L1ZTNeMFWr

• Lupus Topic Panel | RheumNow

Methotrexate: shall we split up? Methotrexate (MTX) is widely used in rheumatic diseases yet poses common tolerance issues, especially for the oral form; and bioavailability is known to be limited for doses over 15mg. https://t.co/yxvI9Q0B9m https://t.co/MxPQ4DAGsj

• Methotrexate: shall we split up? | RheumNow